PR
iPROMOMED
PRMD.ME · MCX
390.55 ₽ +0.19% (+0.75 ₽)
1M +1.37%
Market Cap 83.0B ₽
P/E Ratio 28.68x
Div. Yield -
ROE -
Valuation
47 /100
Fair EV/EBITDA 12.53x
P/S 3.87x
P/B 4.29x
Growth
43 /100
Stable Rev. growth 9.42%
Book val. growth 26.69%
EPS growth 21.73%
Profitability
66 /100
Moderate Net margin 13.49%
Op. margin 32.15%
FCF margin 18.51%
Quality
50 /100
Average ROA 5.45%
Asset turnover 0.40x
ROIC 9.86%
Debt
57 /100
Moderate Current ratio 2.11x
Int. coverage 2.79x
Net debt/EBITDA 2.12x
Stability
77 /100
Stable Rev. volatility 25.09%
EPS volatility 14.48%
Profitable years 4
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na PRMD.ME
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Nimesh Shah
Employees
2,000
Headquarters
-